The poster at ILC 2022 will highlight the development of Aspect’s bioengineered liver tissue therapeutic
Vancouver, BC, Canada - June 22, 2022 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present data from its liver tissue therapeutic program at the International Liver Congress™ (ILC) 2022, hosted by the European Association for the Study of the Liver (EASL), held June 22-26, 2022 in London, UK and virtually.
"The data we are presenting demonstrates that our bioengineered liver tissues are highly functional in animal models,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “This progress is paving the way for the creation of an entirely new class of regenerative medicine capable of addressing the huge unmet medical need that exists with liver failure and genetic liver diseases."
Poster Presentation Details:
3D Bioprinted Hepatocyte and Mesenchymal Stem Cell Spheroids as a Cell Therapy for Liver Disease
- Date/Time: Saturday, June 25, 2022 9:00-18:00 GMT+1
- Session: Molecular and Cellular Biology
- Abstract Number: 3428
- Presented by: Dr. Sam Wadsworth, Chief Scientific Officer, Aspect Biosystems
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioengineered tissue therapeutics to transform how we treat disease. Aspect is leveraging its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science to create a pipeline of allogeneic cell-based tissue therapeutics that replace or repair damaged organ functions. These therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at www.aspectbiosystems.com.